As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Biomarin Pharmaceutical Inc. The largest reported stake is BlackRock, Inc.'s, at 10%. 7 filings are on record since August 14, 2025 (Schedule 13G/A, November 4, 2026).
Sell to companies like Biomarin Pharmaceutical Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 18,549,911 · Shared voting: 0 · Sole dispositive: 19,373,309 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-04
- · Reporting person: Vanguard Capital Management · Sole voting: 1,470,055 · Shared voting: 0 · Sole dispositive: 10,113,219 · Shared dispositive: 0 · SCHEDULE 13G, 2026-04-29
- · Reporting person: The Vanguard Group · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-03-26
- · Holder: BlackRock, Inc. · Percent: 9.1% · SCHEDULE 13G/A
- · Reporting person: Viking Global Investors LP · Sole voting: 0 · Shared voting: 8,322,179 · Sole dispositive: 0 · Shared dispositive: 8,322,179 · SCHEDULE 13G/A, 2025-11-14
Biomarin Pharmaceutical Inc has 7 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 10% | 19,373,309 | SCHEDULE 13G/A, 2026-11-04 | 2026-10-31 |
| Primecap Management Co | 8.24% | 15,795,383 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Vanguard Capital Management | 5.25% | 10,113,219 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| Viking Global Investors LP | 4.3% | 8,322,179 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Biomarin Pharmaceutical Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Biomarin Pharmaceutical Inc and the records around it.
Biomarin Pharmaceutical Inc elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- PRIMECAP MANAGEMENT CO/CA/ also filed stake reports on 24 other companies: Xencor Inc (Nov 2026), GRAIL, Inc. (Nov 2026), MARKETAXESS HOLDINGS INC (Nov 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Watch Biomarin Pharmaceutical Inc
Get an email when Biomarin Pharmaceutical Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Biomarin Pharmaceutical Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Biomarin Pharmaceutical Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Biomarin Pharmaceutical Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 18,549,911 | 0 | 19,373,309 | 0 | SCHEDULE 13G/A, 2026-11-04 |
| Vanguard Capital Management | 1,470,055 | 0 | 10,113,219 | 0 | SCHEDULE 13G, 2026-04-29 |
| Viking Global Investors LP | 0 | 8,322,179 | 0 | 8,322,179 | SCHEDULE 13G/A, 2025-11-14 |
| Viking Global Performance LLC | 0 | 5,397,003 | 0 | 5,397,003 | SCHEDULE 13G/A, 2025-11-14 |
| Viking Global Equities II LP | 0 | 107,937 | 0 | 107,937 | SCHEDULE 13G/A, 2025-11-14 |
| Viking Global Equities Master Ltd. | 0 | 5,289,066 | 0 | 5,289,066 | SCHEDULE 13G/A, 2025-11-14 |
| Viking Long Fund GP LLC | 0 | 2,094,037 | 0 | 2,094,037 | SCHEDULE 13G/A, 2025-11-14 |
| Viking Long Fund Master Ltd. | 0 | 2,094,037 | 0 | 2,094,037 | SCHEDULE 13G/A, 2025-11-14 |
| Viking Global Opportunities Parent GP LLC | 0 | 831,139 | 0 | 831,139 | SCHEDULE 13G/A, 2025-11-14 |
| Viking Global Opportunities GP LLC | 0 | 831,139 | 0 | 831,139 | SCHEDULE 13G/A, 2025-11-14 |
| Viking Global Opportunities Portfolio GP LLC | 0 | 831,139 | 0 | 831,139 | SCHEDULE 13G/A, 2025-11-14 |
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0 | 831,139 | 0 | 831,139 | SCHEDULE 13G/A, 2025-11-14 |
| Halvorsen Ole Andreas | 0 | 8,322,179 | 0 | 8,322,179 | SCHEDULE 13G/A, 2025-11-14 |
| Ott David C. | 0 | 8,322,179 | 0 | 8,322,179 | SCHEDULE 13G/A, 2025-11-14 |
| Shabet Rose Sharon | 0 | 8,322,179 | 0 | 8,322,179 | SCHEDULE 13G/A, 2025-11-14 |
| The Vanguard Group | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-03-26 |
The latest filing identifies Biomarin Pharmaceutical Inc by CUSIP 09061G101 and gives its principal executive office as 770 Lindaro Street, San Rafael, CA 94901 (SCHEDULE 13G/A, 2026-11-04).
What the percentages are based on
The percentages set forth herein are based on 192,098,751 shares of Common Stock outstanding as of September 30, 2025, as reported by the Issuer in its quarterly report on Form 10-Q, filed with the U.S.Viking Global Investors LP, SCHEDULE 13G/A, 2025-11-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Viking Global Investors LP | 6.4% | SCHEDULE 13G/A |
| 2025-08-14 | Primecap Management Co | 8.24% | SCHEDULE 13G/A |
| 2025-11-14 | Viking Global Investors LP | 4.3% | SCHEDULE 13G/A |
| 2026-01-21 | BlackRock, Inc. | 9.1% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Capital Management | 5.25% | SCHEDULE 13G |
| 2026-11-04 | BlackRock, Inc. | 10% | SCHEDULE 13G/A |
Questions about who owns Biomarin Pharmaceutical Inc
Who owns Biomarin Pharmaceutical Inc?
On this page, 3 holders' latest ownership filings report 5% or more of Biomarin Pharmaceutical Inc: BlackRock, Inc. (10%, Schedule 13G/A, filed 2026-11-04), Primecap Management Co (8.24%, Schedule 13G/A, filed 2025-08-14) and Vanguard Capital Management (5.25%, Schedule 13G, filed 2026-04-29).
Who are the largest shareholders of Biomarin Pharmaceutical Inc?
By the share each holder's latest filing reports, the largest holders of Biomarin Pharmaceutical Inc on this page are BlackRock, Inc. (10%), Primecap Management Co (8.24%) and Vanguard Capital Management (5.25%).
When did BlackRock, Inc. buy into Biomarin Pharmaceutical Inc?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G/A, filed 2026-01-21, reporting 9.1%; its latest, Schedule 13G/A filed 2026-11-04, reports 10%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Biomarin Pharmaceutical Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 14, 2026 | Leadership change: Robert Plenge appointed | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Biomarin Pharmaceutical Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.